Abstract
The article describes a wide spectrum of biological agents for treatment of Immune-mediated inflammatory rheumatic diseases in clinical practice in EU. Pharmacological classification, main characteristics of anti-TNF agents and biologics with another modes of action, as well as the most important results of clinical trials are provided. Authors focused on the use of biological agents in clinical practice in emerging market regions such as Central and Eastern Europe, particularly in Romania, were disparity due to economic and social factors provides challenges to achieving optimal monitoring and physician’s decision making. Such very important points as an adoption of «treat to target» recommendations to local practice, consensus guidelines on the criteria for biological treatment, patient education initiatives, the development of a national patients registry, are discussed.
Highlights
The results showed significant clinical improvements after 1 year of treatment, and the safety profile was favorable
There are several emerging market regions ê including Romania ê that have committed to these types of initiatives, with the goal of decreasing the burden of immune-mediated inflammatory diseases
A second important step in decreasing treatment disparities is for rheumatologists to adapt their strategies to fit the ACR/EULAR guidelines for treating to target [71]
Summary
Adalimumab is a completely humanized anti-TNF-α monoclonal Ab. The dose is 40 mg every 2 weeks, administered subcutaneously. Other studies have looked into the benefic effects and the safety of the treatment with Adalimumab combined with MTX or another disease-modifying agent or as monotherapy, from a clinical point of view, and from a radiologic one, at 24 weeks or on the long term, in the early and late phases of RA [15,16,17,18].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
